Piper Jaffray
Piper Jaffray is a client-focused, middle market investment bank and institutional securities firm founded in 1895 and based in Minneapolis, Minnesota.
Its Investment Banking activities include raising capital through equity and debt financings for corporate clients; providing financial advisory services relating to mergers and acquisitions to consumer, financial institutions, health care, technology, alternative energy, business services, and industrial growth sectors; underwriting debt issuances for government and non-profit clients; and providing financial advisory and interest rate risk management services.
The company's equity and fixed income institutional sales and trading activities include equity and fixed income advisory and trade execution services for public and private corporations, public entities, non-profit clients, and institutional investors.
-
Notable Analyst Rating Changes 09/06: (AKS) (ATVI) (GOLD) Upgraded; (NOK) (CLF) (OCZ) Downgraded
-
Arena Pharma (ARNA) Higher as M&A Chatter Heats Up
-
Arena Pharmaceuticals (ARNA) Trades Down Following Stock Offering
-
Piper Jaffray Upgrades Arena Pharma (ARNA) to Overweight
-
Morning Movers 03/28: (AMLN) (PNR) (YELP) (TNK) Higher; (FSM) (ALIM) (SNX) (CBK) Lower
-
Notable Analyst Rating Changes 03/28: (FRO) (ARO) (DTV) Upgraded; (ARNA) (VZ) (WFT) Downgraded
-
Arena (ARNA) Shares Sink as Piper Jaffray Downgrade Weighs
-
Piper Jaffray Cuts Arena Pharma (ARNA) to Neutral
-
Piper Jaffray Upgrades Arena Pharma (ARNA) to Overweight
-
Morning Movers 01/28: CHMP, TMRK, OPLK, BGP, TNAV, ARAY, SVVS, ARBA, EPAY Higher; AEN, MWW, BNVI, INFN, TSRA, ARNA Lower
-
Notable Analyst Rating Changes 09/17: VITA, ORCL, CTL, OSK Upgraded; ARNA, MELI, ARRS, SPN Downgraded
-
Piper Jaffray Cuts Arena Pharma (ARNA) to Neutral, Price Target Slashed to $1.50
-
Jefferies, BMO Issue Afternoon Downgrades on Arena Pharma (ARNA)
-
Analyst Round-Up Arena Pharma (ARNA): Downgraded at Barclays, Oppenheimer, Defended by Piper Jaffray
-
Piper Jaffray Says Arena Pharmaceuticals (ARNA) Sell-Off is an "Overreaction"
-
Piper Jaffray Tells Clients to Buy Arena Pharmaceuticals (ARNA) Ahead of 9/16 FDA FDA Meeting
-
Piper Jaffray Reiterates an 'Overweight' Rating on Arena Pharma (ARNA) Ahead of FDA Panel
-
Arena Pharmaceuticals (ARNA): Upgraded to Overweight at J.P. Morgan
-
Piper Jaffray Raises Price Target on Arena Pharma (ARNA) to $10 Following Eisai Agreement
-
Morning Movers 7/8: TRGT, HNAB, AMGN, NTWK, FDO Higher; ARYX, XNPT, ARNA, AXL Lower
-
Arena Pharmaceuticals (ARNA) Prices 12.5M Shares at $4.17
-
Arena Pharmaceuticals (ARNA) To File Mixed Securities Shelf
